Middlemen have outsized influence on US drug prices, FTC says
Adds UnitedHealth comment in paragraph 6
By Ahmed Aboulenein and Jody Godoy
WASHINGTON, July 9 (Reuters) -The consolidation of pharmacies and health insurance companies through years of dealmaking has led to a handful of pharmacy benefit managers exercising outsized influence over prescription drug prices, the U.S. Federal Trade Commission said on Tuesday.
Pharmacy benefit managers, or PBMs, act as middlemen between drug companies and consumers. They negotiate volume discounts and fees with drug manufacturers, create lists of medications that are covered by insurance, and reimburse pharmacies for prescriptions.
The FTC argues the three biggest PBMs - managing 79% of U.S. prescription drug claims - have greatly enriched themselves at the expense of smaller pharmacies and consumers, according to an interim staff report calling for possible greater regulation.
"These powerful middlemen may be profiting by inflating drug costs and squeezing Main Street pharmacies," the FTC said in its findings, two years into an investigation of top PBMs and their impact on prescription drug prices in the United States.
The three biggest PBMs are UnitedHealth Group Inc's UNH.N Optum unit, CVS Health Corp's CVS.N CVS Caremark and Cigna Corp's CI.N Express Scripts.
UnitedHealth, CVS,and Express Scripts denounced the findings. Express Scriptssaid the report contained "blatant" inaccuracies and its conclusions were biased. Increased regulation of PBMs would reward drugmakers and hurt consumers, CVS said. The FTC published an incomplete report with flawed conclusion, said Optum Rx.
PBM shares slipped upon the report's release, with CVS down 1%, Humana falling 1.2%, and UnitedHealth down marginally.
The report included some closely guarded information about how companies contract for formulary placement for drugs.
Formulary drugs is the term used for the list of medications covered by various insurance plans.
The report also detailed how the three largest PBMs recently established separate affiliated entities called group purchasing organizations, or PBM GPOs, that negotiate contracts and rebates with drugmakers, traditionally something the PBMs engaged in directly. A CVS spokesperson said the company uses its GPO, Zinc, to lower prices for Caremark clients. Cigna did not address the issue in its response to Reuters questions.
RENEWED EFFORT
The report comes amid a renewed effort by U.S. President Joe Biden to combat soaring healthcare costs and drug prices after the passage of his landmark Inflation Reduction Act.
The PBM market has become highly concentrated with the largest companies being vertically integrated with the largest insurance companies and pharmacy chains. This has given PBMs significant power over prescription drug prices and the ability of Americans to access them, the FTC said.
PBMs set which drugs are covered by insurance and at what price, as well as which pharmacies patients can use to fill their prescriptions. They do this without transparency or public accountability, the report said.
Of the three biggest PBMs, CVS owns the nation's largest retail pharmacy chain, as well as insurance company Aetna. UnitedHealth and Cigna also have insurance units and own specialty pharmacies.
The FTC also investigated Humana Pharmacy Solutions, Prime Therapeutics and MedImpact Healthcare Systems. These six companies together control over 90% of the market
Prime Therapeutics said it was not owned or affiliated with any single insurer or pharmacy. MedImpact did not respond to requests for comment and Humana declined to comment.
The market consolidation has led to PBMs favoring their own affiliated businesses, which creates conflicts of interest that prevent smaller independent pharmacies from staying competitive by steering patients away from them, the FTC said.
PBMs are also able to lock independent pharmacies into unfair contracts that do not accurately reflect the final payment amounts these pharmacies will get, the FTC said.
CVS said independent pharmacies account for 30% of Caremark's pharmacy network spend and that they are on average reimbursed at a higher rate than CVS pharmacies.
The FTC said it found evidence that PBMs and the makers of brand drugs negotiate rebates - volume-based discounts for plans and pharmacies - conditioned on limiting access to cheaper generic competitors.
Several PBMs were issued orders to hand over data but were not forthcoming and timely in their responses, the report said, which has hindered the investigation.
CVS said it complied with all data requests. Cigna said it provided the agency with millions of lines of data and documents. UnitedHealth said it handed the FTC six years worth of data. Prime said it fully complied with the agency's requests.
Reporting by Ahmed Aboulenein in Washington and Jody Godoy in New York; Additional reporting by Patrick Wingrove and Amina Niasse in New York; Editing by Caroline Humer, Leslie Adler, Susan Fenton and Aurora Ellis
Gerelateerde activa
Laatste nieuws
Disclaimer: De entiteiten van de XM Group bieden diensten en toegang tot ons online handelsplatform op basis van uitsluitend-uitvoering, waardoor een persoon de beschikbare content op of via de website kan bekijken en/of gebruiken, zonder dat dit is bedoeld voor wijziging of uitbreiding. Dergelijk(e) toegang en gebruik vallen onder: (i) de algemene voorwaarden; (ii) risicowaarschuwingen; en de (iii) volledige disclaimer. Dergelijke content wordt daarom alleen aangeboden als algemene informatie. Wees u er daarnaast vooral van bewust dat de inhoud op ons online handelsplatform geen verzoek of aanbieding omvat om transacties op de financiële markten uit te voeren. Het beleggen op welke financiële markt dan ook vormt een aanzienlijk risico voor uw vermogen.
Alle materialen die op ons online handelsplatform worden gepubliceerd zijn bedoeld voor educatieve/informatieve doeleinden en omvatten geen – en moeten niet worden beschouwd als het bevatten van – financieel, vermogensbelastings- of handelsadvies en aanbevelingen, of een overzicht van onze handelsprijzen, of een aanbod of aanvraag van een transactie in financiële instrumenten of ongevraagde financiële promoties voor u.
Alle content van derden, alsmede content die is voorbereid door XM, zoals opinies, nieuws, onderzoeken, analyses, prijzen en andere informatie of koppelingen naar externe websites op deze website worden aangeboden op een 'zoals-ze-zijn'-basis, als algemene marktcommentaren, en vormen geen beleggingsadvies. Voor zover dat content wordt beschouwd als beleggingsonderzoek, moet u zich ervan bewust zijn en accepteren dat de content niet bedoeld was en niet is voorbereid in overeenstemming met de wettelijke vereisten die zijn opgesteld om de onafhankelijkheid van beleggingsonderzoek te bevorderen en als zodanig onder de geldende wetgeving en richtlijnen moet worden beschouwd als marketingcommunicatie. Zorg ervoor dat u onze Mededeling over niet-onafhankelijk beleggingsonderzoek en risicowaarschuwing in verband met de voorgaande informatie doorneemt en begrijpt; die kunt u hier lezen.
